New nerve graft offers hope for men with lasting ED after prostate cancer surgery
NCT ID NCT07188064
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a surgical technique that grafts nerves to help men who have had lasting erectile dysfunction (ED) for over 18 months after prostate cancer surgery. About 100 men will receive the procedure and be followed for one year to see if their erections improve and if the surgery is safe. The goal is to restore natural erectile function without relying on long-term medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jewish General Hospital
RECRUITINGMontreal, Quebec, H3T 1E2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••